BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 30923955)

  • 1. Tolerability and safety of long-term rituximab treatment in systemic inflammatory and autoimmune diseases.
    Vikse J; Jonsdottir K; Kvaløy JT; Wildhagen K; Omdal R
    Rheumatol Int; 2019 Jun; 39(6):1083-1090. PubMed ID: 30923955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
    Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J;
    Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
    Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X;
    Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia: A Retrospective Study of 21 Cases.
    Jiang B; Li T; Guo L; Shen H; Ye S; Chen S
    J Clin Rheumatol; 2015 Aug; 21(5):244-50. PubMed ID: 26203828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.
    Gottenberg JE; Cinquetti G; Larroche C; Combe B; Hachulla E; Meyer O; Pertuiset E; Kaplanski G; Chiche L; Berthelot JM; Gombert B; Goupille P; Marcelli C; Feuillet S; Leone J; Sibilia J; Zarnitsky C; Carli P; Rist S; Gaudin P; Salliot C; Piperno M; Deplas A; Breban M; Lequerre T; Richette P; Ghiringhelli C; Hamidou M; Ravaud P; Mariette X;
    Ann Rheum Dis; 2013 Jun; 72(6):1026-31. PubMed ID: 23264337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus.
    Olfat M; Silverman ED; Levy DM
    Lupus; 2015 Aug; 24(9):966-72. PubMed ID: 25804672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?
    Galarza C; Valencia D; Tobón GJ; Zurita L; Mantilla RD; Pineda-Tamayo R; Rojas-Villarraga A; Rueda JC; Anaya JM
    Clin Rev Allergy Immunol; 2008 Feb; 34(1):124-8. PubMed ID: 18270866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
    Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
    J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.
    Md Yusof MY; Vital EM; McElvenny DM; Hensor EMA; Das S; Dass S; Rawstron AC; Buch MH; Emery P; Savic S
    Arthritis Rheumatol; 2019 Nov; 71(11):1812-1823. PubMed ID: 31131994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Auto-immune diseases and immunodepressive therapy. II. Current clinical indications].
    Delespesse G; Kennes B; Duchateau J
    Acta Clin Belg; 1974; 29(6):413-23. PubMed ID: 4155218
    [No Abstract]   [Full Text] [Related]  

  • 11. Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008-2016.
    Wongseelashote S; Tayal V; Bourke PF
    Intern Med J; 2018 Feb; 48(2):165-172. PubMed ID: 28742259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.
    Seror R; Sordet C; Guillevin L; Hachulla E; Masson C; Ittah M; Candon S; Le Guern V; Aouba A; Sibilia J; Gottenberg JE; Mariette X
    Ann Rheum Dis; 2007 Mar; 66(3):351-7. PubMed ID: 16950808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab and lupus interstitial lung disease: friend or foe?
    Efthimiou P; Kukar M; Hersh A
    Int J Rheum Dis; 2011 Feb; 14(1):e3-4. PubMed ID: 21303472
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-Term Safety of Rituximab in Granulomatosis With Polyangiitis and in Microscopic Polyangiitis.
    Merkel PA; Niles JL; Mertz LE; Lehane PB; Pordeli P; Erblang F
    Arthritis Care Res (Hoboken); 2021 Sep; 73(9):1372-1378. PubMed ID: 32475029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective treatment of autoimmune diseases with extremely low dose cyclosporine.
    Sugiyama M; Sekigawa I; Tokano Y; Iida N; Hashimoto H; Hirose S
    Nihon Rinsho Meneki Gakkai Kaishi; 1998 Feb; 21(1):20-8. PubMed ID: 9884547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab therapy in primary Sjögren's syndrome with interstitial lung disease: a retrospective cohort study.
    Chen MH; Chen CK; Chou HP; Chen MH; Tsai CY; Chang DM
    Clin Exp Rheumatol; 2016; 34(6):1077-1084. PubMed ID: 27607895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus.
    Iwata S; Saito K; Hirata S; Ohkubo N; Nakayamada S; Nakano K; Hanami K; Kubo S; Miyagawa I; Yoshikawa M; Miyazaki Y; Yoshinari H; Tanaka Y
    Lupus; 2018 Apr; 27(5):802-811. PubMed ID: 29308726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical use of immunosuppressive drugs in autoimmune rheumatic diseases.
    De Jesus A; Talal N
    Crit Care Med; 1990 Feb; 18(2 Suppl):S132-7. PubMed ID: 2298028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.
    De Vita S; Quartuccio L; Salvin S; Picco L; Scott CA; Rupolo M; Fabris M
    Clin Exp Rheumatol; 2014; 32(4):490-4. PubMed ID: 24802131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults.
    McAtee CL; Lubega J; Underbrink K; Curry K; Msaouel P; Barrow M; Muscal E; Lotze T; Srivaths P; Forbes LR; Allen C; Bernhardt MB
    JAMA Netw Open; 2021 Feb; 4(2):e2036321. PubMed ID: 33533931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.